CRISPR Delivered Anti-BCMA CAR-T
A Phase 1b Clinical Trial of CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma
Arms / Cohorts
Experimental:Dose Escalation: Planned Dose
Accepting patients
Experimental:Dose Expansion: Maximum Tolerated Dose
Accepting patients
Experimental:Dose Escalation: Starting Dose
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.